{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:51:30Z","timestamp":1792900290981,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Health Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Our aim was to assess the efficacy and safety of Rezum therapy in patients with symptomatic benign prostatic hyperplasia (BPH) in comparison to Holmium laser enucleation of the prostate (HoLEP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The retrospective study included 338 patients (204 HoLEP and 134 Rezum) operated on for BPH between January 2020 and November 2024. A 1:1 matching of treated patients (Rezum) to HoLEP patients based on the closest propensity score value was conducted for 131 successful matching pairs. The groups were compared regarding; Age, Prostate volume, PSA, Catheter-dependence, Qmax, PVR, IIEF, IPSS, PGI-I, operation time (OT) and hospital time (HS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Concerning perioperative data, there was a statistically significant difference between the Rezum and HoLEP groups regarding OT (8.29\u2009\u00b1\u20091.21 vs. 68.01\u2009\u00b1\u200931.01\u00a0min;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and HS (1 vs. 2.61\u2009\u00b1\u20091.53 days;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) with higher values for HoLEP. At the same time, the catheter duration was longer in the Rezum group (7.6\u2009\u00b1\u20092.19 vs. 3.49\u2009\u00b1\u20091.16 days;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). In terms of clinical outcomes, there was a statistically significant improvement in Qmax, IPSS and a decrease in PVR at 12 months for the HoLEP group compared to the Rezum group (16.82\u2009\u00b1\u20092.27\u00a0ml\/sn vs. 22.14\u2009\u00b1\u20097.17\u00a0ml\/sn,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001; 12.1\u2009\u00b1\u20092.1 vs. 7.1\u2009\u00b1\u20091.9,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001; 43.05\u2009\u00b1\u200932.62\u00a0ml vs. 29.73\u2009\u00b1\u200943.73\u00a0ml,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.006; respectively). PGI-I scores (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.620) and antegrade ejaculation (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) were in favour of Rezum therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The HoLEP technique demonstrates superior functional outcomes compared to Rezum, particularly in cases with larger prostates. However, Rezum is an ejaculation-sparing technique demonstrating high tolerability, and patient satisfaction even in larger prostates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-025-05644-y","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T17:01:53Z","timestamp":1745341313000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of outcome for holmium laser enucleation prostate and Rezum system in benign prostate hyperplasia: a matched pair analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3659-1319","authenticated-orcid":false,"given":"Orkunt","family":"\u00d6zkaptan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6321-5143","authenticated-orcid":false,"given":"C\u00fcneyd","family":"Sevin\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2654-1986","authenticated-orcid":false,"given":"Cengiz","family":"\u00c7anakc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2000-7790","authenticated-orcid":false,"given":"Tahsin Batuhan","family":"Aydo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3467-5881","authenticated-orcid":false,"given":"O\u011fuz","family":"T\u00fcrky\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8052-5437","authenticated-orcid":false,"given":"Mahmut Selman","family":"Mert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9322-9717","authenticated-orcid":false,"given":"Alkan","family":"\u00c7ubuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"5644_CR1","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.juro.2008.03.141","volume":"173","author":"JT Wei","year":"2005","unstructured":"Wei JT, Calhoun E, Jacobsen SJ (2005) Urologic diseases in America project: benign prostatic hyperplasia. J Urol 173:1256\u20131261. https:\/\/doi.org\/10.1016\/j.juro.2008.03.141","journal-title":"J Urol"},{"key":"5644_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000200786","volume":"82","author":"RM Mavuduru","year":"2009","unstructured":"Mavuduru RM, Mandal AK, Singh SK et al (2009) Comparison of holep and TURP in terms of efficacy in the early postoperative period and peri-operative morbidity. Urol Int 82:130\u2013135. https:\/\/doi.org\/10.1159\/000200786","journal-title":"Urol Int"},{"key":"5644_CR3","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/bjs.5916","volume":"94","author":"A Tan","year":"2007","unstructured":"Tan A, Liao C, Mo Z et al (2007) Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. Br J Surg 94:1201\u20131208. https:\/\/doi.org\/10.1002\/bjs.5916","journal-title":"Br J Surg"},{"key":"5644_CR4","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1464-410X.2011.10359.x","volume":"109","author":"PJ Gilling","year":"2012","unstructured":"Gilling PJ, Wilson LC, King CJ et al (2012) Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years. BJU Int 109:408\u2013411. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10359.x","journal-title":"BJU Int"},{"key":"5644_CR5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1089\/end.2014.0502","volume":"29","author":"J Placer","year":"2015","unstructured":"Placer J, Salvador C, Planas J et al (2015) Effects of holmium laser enucleation of the prostate on sexual function. J Endourol 29:332\u2013339. https:\/\/doi.org\/10.1089\/end.2014.0502","journal-title":"J Endourol"},{"key":"5644_CR6","doi-asserted-by":"publisher","first-page":"873","DOI":"10.4103\/1008-682X.132469","volume":"16","author":"SH Kim","year":"2014","unstructured":"Kim SH, Yang HK, Lee HE et al (2014) HoLEP does not affect the overall sexual function of BPH patients: a prospective study. Asian J Androl 16:873\u2013877. https:\/\/doi.org\/10.4103\/1008-682X.132469","journal-title":"Asian J Androl"},{"key":"5644_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/MOU.0000000000000498","volume":"28","author":"T Large","year":"2018","unstructured":"Large T, Krambeck AE (2018) Evidence-based outcomes of holmium laser enucleation of the prostate. Curr Opin Urol 28:301\u2013308. https:\/\/doi.org\/10.1097\/MOU.0000000000000498","journal-title":"Curr Opin Urol"},{"key":"5644_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/JU.0000000000001298","volume":"204","author":"JK Parsons","year":"2020","unstructured":"Parsons JK, Dahm P, Kohler TS et al (2020) Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2020. J Urol 204:799\u2013804. https:\/\/doi.org\/10.1097\/JU.0000000000001298","journal-title":"J Urol"},{"key":"5644_CR9","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.juro.2016.12.045","volume":"197","author":"CG Roehrborn","year":"2017","unstructured":"Roehrborn CG, Gange SN, Gittelman MC et al (2017) Convective thermal therapy:durable 2 year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol 197:1507\u20131516. https:\/\/doi.org\/10.1016\/j.juro.2016.12.045","journal-title":"J Urol"},{"key":"5644_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urology.2017.10.023","volume":"111","author":"KT McVary","year":"2018","unstructured":"McVary KT, Roehrborn CG (2018) Three-year outcomes of the prospective, randomized controlled Rez\u016bm system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology 111:1\u20139. https:\/\/doi.org\/10.1016\/j.urology.2017.10.023","journal-title":"Urology"},{"key":"5644_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2018.12.041","volume":"126","author":"KT McVary","year":"2019","unstructured":"McVary KT, Rogers T, Roehrborn CG (2019) Rez\u016bm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4 year results from randomized controlled study. Urology 126:171\u2013179. https:\/\/doi.org\/10.1016\/j.urology.2018.12.041","journal-title":"Urology"},{"key":"5644_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/RRU.S119596","volume":"8","author":"CM Dixon","year":"2016","unstructured":"Dixon CM, Cedano ER, Pacik D et al (2016) Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol 8:207\u2013216. https:\/\/doi.org\/10.2147\/RRU.S119596","journal-title":"Res Rep Urol"},{"key":"5644_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/1756287218793084","volume":"10","author":"J Westwood","year":"2018","unstructured":"Westwood J, Geraghty R, Jones P et al (2018) Rez\u016bm: a new transurethral water vapour therapy for benign prostatic hyperplasia. Ther Adv Urol 10:327\u2013333. https:\/\/doi.org\/10.1177\/1756287218793084","journal-title":"Ther Adv Urol"},{"key":"5644_CR14","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s00345-019-02671-4","volume":"37","author":"G Saitta","year":"2019","unstructured":"Saitta G, Becerra JEA, Del \u00c1lamo JF et al (2019) En bloc\u2019 holep with early apical release in men with benign prostatic hyperplasia. World J Urol 37:2451\u20132458. https:\/\/doi.org\/10.1007\/s00345-019-02671-4","journal-title":"World J Urol"},{"key":"5644_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.23736\/S0393-2249.19.03588-4","volume":"71","author":"GE Cacciamani","year":"2019","unstructured":"Cacciamani GE, Cuhna F, Tafuri A et al (2019) Anterograde ejaculation preservation after endoscopic treatments in patients with bladder outlet obstruction: systematic review and pooled-analysis of randomized clinical trials. Minerva Urol Nefrol 71:427\u2013434. https:\/\/doi.org\/10.23736\/S0393-2249.19.03588-4","journal-title":"Minerva Urol Nefrol"},{"key":"5644_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.23736\/S0393-2249.20.03654-1","volume":"72","author":"C Fiori","year":"2020","unstructured":"Fiori C, Checcucci E, Gilling P et al (2020) All you need to know about aquablation procedure for treatment of benign prostatic obstruction. Minerva Urol Nefrol 72:152\u2013161. https:\/\/doi.org\/10.23736\/S0393-2249.20.03654-1","journal-title":"Minerva Urol Nefrol"},{"key":"5644_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.23736\/S2724-6051.22.04861-3","volume":"74","author":"G Siena","year":"2022","unstructured":"Siena G, Tellini R, Cindolo L (2022) Can Rezum stand out as the most versatile and better performing minimally invasive treatment for the management of LUTS related to BPH? Minerva Urol Nephrol 74:499\u2013501. https:\/\/doi.org\/10.23736\/S2724-6051.22.04861-3","journal-title":"Minerva Urol Nephrol"},{"key":"5644_CR18","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s00345-020-03457-9","volume":"39","author":"A Arezki","year":"2021","unstructured":"Arezki A, Sadri I, Couture F et al (2021) Reasons to go for Rez\u016bm steam therapy: an effective and durable outpatient minimally invasive procedure. World J Urol 39:2307\u20132313. https:\/\/doi.org\/10.1007\/s00345-020-03457-9","journal-title":"World J Urol"},{"key":"5644_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.23736\/S2724-6051.22.05080-7","volume":"75","author":"L Cindolo","year":"2023","unstructured":"Cindolo L, Morselli S, Campobasso D et al (2023) One-year outcomes after water vapor thermal therapy for symptomatic benign prostatic hyperplasia in an unselected Italian multicenter cohort. Minerva Urol Nephrol 75:203\u2013209. https:\/\/doi.org\/10.23736\/S2724-6051.22.05080-7","journal-title":"Minerva Urol Nephrol"},{"key":"5644_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/iju.15410","volume":"31","author":"M Samir","year":"2024","unstructured":"Samir M, Elaal AAA, Gad KAS et al (2024) Two-year follow-up comparing Rez\u016bm therapy versus bipolar transurethral resection of the prostate for treating benign prostatic hyperplasia. A prospective randomized study. Int J Urol 31:545\u2013550. https:\/\/doi.org\/10.1111\/iju.15410","journal-title":"Int J Urol"},{"key":"5644_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11845-021-02552-z","volume":"191","author":"UM Haroon","year":"2022","unstructured":"Haroon UM, Khan JS, McNicholas D et al (2022) Introduction of Rezum system technology to Ireland for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a pilot study on early outcomes and procedure cost analysis. Ir J Med Sci 191:421\u2013426. https:\/\/doi.org\/10.1007\/s11845-021-02552-z","journal-title":"Ir J Med Sci"},{"key":"5644_CR22","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.eururo.2007.01.088","volume":"52","author":"M Muntener","year":"2007","unstructured":"Muntener M, Aellig S, Kuettel R et al (2007) Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicentre assessment of outcome. Eur Urol 52:510\u2013515. https:\/\/doi.org\/10.1016\/j.eururo.2007.01.088","journal-title":"Eur Urol"},{"key":"5644_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.urology.2014.04.042","volume":"84","author":"DE Klett","year":"2014","unstructured":"Klett DE, Tyson MD 2nd, Mmeje CO et al (2014) Patient-reported sexual outcomes after holmium laser enucleation of the prostate: a 3-year follow-up study. Urology 84:421\u2013426. https:\/\/doi.org\/10.1016\/j.urology.2014.04.042","journal-title":"Urology"},{"key":"5644_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1089\/end.2020.0739","volume":"35","author":"K Tanneru","year":"2021","unstructured":"Tanneru K, Jazayeri SB, Alam MU et al (2021) An indirect comparison of newer minimally invasive treatments for benign prostatic hyperplasia: A network Meta-Analysis model. J Endourol 35:409\u2013416. https:\/\/doi.org\/10.1089\/end.2020.0739","journal-title":"J Endourol"},{"key":"5644_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.5489\/cuaj.5616","volume":"12","author":"JC Nickel","year":"2018","unstructured":"Nickel JC, Aaron L, Barkin J et al (2018) Canadian urological association guideline on male lower urinary tract symptoms\/benign prostatic hyperplasia (MLUTS\/BPH): 2018 update. Can Urol Assoc J 12:303\u2013312. https:\/\/doi.org\/10.5489\/cuaj.5616","journal-title":"Can Urol Assoc J"},{"key":"5644_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ucl.2021.07.007","volume":"49","author":"D Elterman","year":"2022","unstructured":"Elterman D, Gao B, Lu S et al (2022) New technologies for treatment of benign prostatic hyperplasia. Urol Clin North Am 49:11\u201322. https:\/\/doi.org\/10.1016\/j.ucl.2021.07.007","journal-title":"Urol Clin North Am"},{"key":"5644_CR27","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1089\/end.2020.0177","volume":"34","author":"R Bole","year":"2020","unstructured":"Bole R, Gopalakrishna A, Kuang R et al (2020) Comparative postoperative outcomes of Rez\u016bm prostate ablation in patients with large versus small glands. J Endourol 34:778\u2013781. https:\/\/doi.org\/10.1089\/end.2020.0177","journal-title":"J Endourol"},{"key":"5644_CR28","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1007\/s00345-020-03548-7","volume":"39","author":"EB Garden","year":"2021","unstructured":"Garden EB, Shukla D, Ravivarapu KT et al (2021) Rezum therapy for patients with large prostates (\u2265\u200980\u00a0g): initial clinical experience and postoperative outcomes. World J Urol 39:3041\u20133048. https:\/\/doi.org\/10.1007\/s00345-020-03548-7","journal-title":"World J Urol"},{"issue":"1","key":"5644_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/end.2022.0490","volume":"37","author":"M Babar","year":"2023","unstructured":"Babar M, Labagnara K, Loloi J et al (2023) Risk factors and Realworld short-term outcomes of a failed trial of void after Rezum therapy in a multiethnic population. J Endourol 37(1):67\u201373. https:\/\/doi.org\/10.1089\/end.2022.0490","journal-title":"J Endourol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05644-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05644-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05644-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:52:14Z","timestamp":1767966734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05644-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5644"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05644-y","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"242"}}